Search Within

Matthew David Hellmann

  1. "2016"
Formats
  1. Meeting Abstract (19)
  2. Journal Article (14)
Groups
  1. Department of Medicine (33)
  2. Solid Tumor Oncology Division (33)
  3. Thoracic Oncology (33)
  4. GSK Faculty (14)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (8)
  6. Department of Pathology and Laboratory Medicine (8)

More Groups

People
  1. Jedd Wolchok (8)
  2. Mark Kris (6)
  3. Charles Rudin (5)
  4. Marc Ladanyi (5)
  5. Taha Merghoub (5)
  6. Jamie Chaft (4)

More People

Years
  1. 2016 (33)
Publications
  1. Journal of Clinical Oncology (10)
  2. Annals of Oncology (7)
  3. Journal for ImmunoTherapy of Cancer (3)
  4. Journal of Thoracic Oncology (2)
  5. Advances in Immunology (1)
  6. Cancer Immunology Research (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (10)
  2. Oxford University Press (7)
  3. Elsevier Inc. (4)
  4. American Association for Cancer Research (3)
  5. Biomed Central Ltd (3)
  6. American Association for the Advancement of Science (1)

More Publishers

Results (33)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Identifying HER2 mutation, amplification, and HER2 protein overexpression as therapeutic targets in lung cancers
    Meeting Abstract

    Li, B. T.; Zheng, T.; Ni, A.; Hellmann, M. D.; Jordan, E.; Barron, D.; Smyth, L. M.; Solit, D. B.; Zehir, A.; Ross, D. S.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Preliminary results of ENCORE 601, a phase 1 b/2, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Johnson, M. L.; Adjei, A. A.; Ramalingam, S. S.; Janne, P. A.; Dominguez, G.; Gabrilovich, D.; Deleon, L.; Hasapidis, J. L.; Diede, S. J.; Ordentlich, P.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro)
    Meeting Abstract

    Hui, R.; Gandhi, L.; Costa, E. C.; Felip, E.; Ahn, M. J.; Eder, J. P.; Balmanoukian, A. S.; Leighl, N. B.; Aggarwal, C.; Horn, L.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC
    Meeting Abstract

    Hellmann, M. D.; Gettinger, S. N.; Goldman, J. W.; Brahmer, J. R.; Borghaei, H.; Chow, L. Q.; Ready, N.; Gerber, D. E.; Juergens, R. A.; Shepherd, F. A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer
    Meeting Abstract

    Forde, P. M.; Smith, K.; Chaft, J. E.; Hellmann, M. D.; Merghoub, T.; Wolchok, J. D.; Yang, S. C.; Battafarano, R. J.; Gabrielson, E.; Georgiades, C.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses
    Meeting Abstract

    Borghaei, H.; Brahmer, J. R.; Horn, L.; Ready, N.; Steins, M.; Felip, E.; Paz-Ares, L. G.; Arrieta, O.; Barlesi, F.; Antonia, S. J.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC)
    Meeting Abstract

    Bendell, J. C.; Kim, T. W.; Goh, B. C.; Wallin, J.; Oh, D. Y.; Han, S. W.; Lee, C. B.; Hellmann, M. D.; Desai, J.; Lewin, J. H.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Genome-scale neoantigen screening using ATLAS™ prioritizes candidates for immunotherapy in a non-small cell lung cancer patient
    Meeting Abstract

    Ghamsari, L.; Flano, E.; Jacques, J.; Liu, B.; Havel, J.; Makarov, V.; Merghoub, T.; Wolchok, J. D.; Hellmann, M. D.; Chan, T. A.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Opposing effects of CTLA-4 and PD-1 blockade on follicular helperlike T cells with immunosuppressive functions
    Meeting Abstract

    Zappasodi, R.; Budhu, S.; Hellmann, M. D.; Postow, M.; Senbabaoglu, Y.; Gasmi, B.; Zhong, H.; Li, Y.; Liu, C.; Hirschhorhn-Cymerman, D.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Dose escalation/confirmation results of ENCORE 601, a phase Ib/II, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Johnson, M. L.; Adjei, A. A.; Opyrchal, M.; Ramalingam, S.; Janne, P. A.; Dominguez, G.; Gabrilovich, D.; de Leon, L.; Hasapidis, J.; Diede, S. J.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save